0001697362-26-000008.txt : 20260429 0001697362-26-000008.hdr.sgml : 20260429 20260429214509 ACCESSION NUMBER: 0001697362-26-000008 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20260427 FILED AS OF DATE: 20260429 DATE AS OF CHANGE: 20260429 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Brophy Michael Burkes CENTRAL INDEX KEY: 0001697362 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-37478 FILM NUMBER: 26919553 MAIL ADDRESS: STREET 1: 13011 MCCALLEN PASS STREET 2: BUILDING A, SUITE 100 CITY: AUSTIN STATE: TX ZIP: 78753 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Natera, Inc. CENTRAL INDEX KEY: 0001604821 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-MEDICAL LABORATORIES [8071] ORGANIZATION NAME: 08 Industrial Applications and Services EIN: 010894487 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 13011 MCCALLEN PASS STREET 2: BUILDING A SUITE 100 CITY: AUSTIN STATE: TX ZIP: 78753 BUSINESS PHONE: 650-249-9090 MAIL ADDRESS: STREET 1: 13011 MCCALLEN PASS STREET 2: BUILDING A SUITE 100 CITY: AUSTIN STATE: TX ZIP: 78753 4 1 form4-04292026_090402.xml X0609 4 2026-04-27 0001604821 Natera, Inc. NTRA 0001697362 Brophy Michael Burkes false C/O NATERA, INC. 13011 MCCALLEN PASS BUILDING A SUITE 100 AUSTIN TX 78753 false true false false CHIEF FINANCIAL OFFICER 1 Common Stock 2026-04-27 4 S 0 771 203.75 D 62583 D Common Stock 2026-04-27 4 S 0 1222 204.39 D 61361 D Common Stock 2026-04-29 4 S 0 300 190.1150 D 61061 D Common Stock 2026-04-29 4 S 0 500 192.1286 D 60561 D Common Stock 2026-04-29 4 S 0 1000 193.7790 D 59561 D Common Stock 2026-04-29 4 S 0 1070 194.8220 D 58491 D Common Stock 2026-04-29 4 S 0 200 197.26 D 58291 D The sale of shares was effected in order to satisfy tax withholding and remittance obligations in connection with the vesting of Restricted Stock Units ("RSUs") and was made pursuant to a written instruction that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act contained in the Reporting Person's Stock Unit Agreement granted on January 26, 2024. The sale of shares was effected in order to satisfy tax withholding and remittance obligations in connection with the vesting of RSUs and was made pursuant to a written instruction that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act contained in the Reporting Person's Stock Unit Agreements granted on January 27, 2023. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 9, 2025, as amended on September 5, 2025. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $190.08 to $190.19 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $191.83 to $192.51 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $193.26 to $194.12 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $194.45 to $195.11 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. /s/ Tami Chen, Attorney-in-Fact 2026-04-29